Decitabine improves patient outcomes in myelodysplastic syndromes

  • Kantarjian H
  • Issa J
  • Rosenfeld C
  • et al.
N/ACitations
Citations of this article
87Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

BACKGROUND. Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters. METHODS. A total of 170 patients with MDS were randomized to receive either decitabine at a dose of 15 mg/m2 given intravenously over 3 hours every 8 hours for 3 days (at a dose of 135 mg/m2 per course) and repeated every 6 weeks, or best supportive care. Response was assessed using the International Working Group criteria and required that response criteria be met for at least 8 weeks. RESULTS. Patients who were treated with decitabine achieved a significantly higher overall response rate (17%), including 9% complete responses, compared with supportive care (0%) (P

Cite

CITATION STYLE

APA

Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., … Saba, H. (2006). Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer, 106(8), 1794–1803. https://doi.org/10.1002/cncr.21792

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free